Allogeneic Cell Therapy Market To Witness 10.2% CAGR Growth Through 2030: Key Industry Drivers
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Allogeneic Cell Therapy Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The allogeneic cell therapy market has seen rapid expansion in recent years. It is forecast to increase from $1.2 billion in 2025 to $1.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to factors such as the restricted supply of allogeneic cell therapy products, the expansion of early-stage clinical trials, the rising incidence of hematological disorders, the increasing adoption of cell therapies by hospitals, and the reliance on donor cell banks.
The allogeneic cell therapy market is poised for significant expansion over the next few years, with projections indicating it will reach $1.97 billion by 2030, exhibiting a robust compound annual growth rate (CAGR) of 10.2%. This anticipated growth during the forecast period can be primarily ascribed to breakthroughs in stem cell and immune cell engineering, the widening scope of dermatological and other therapeutic applications, increased financial input into cell therapy manufacturing plants, strategic alliances between medical institutions and biotechnology enterprises, and the implementation of automated cell processing technologies. Prominent developments anticipated within this forecast timeframe include a greater uptake of stem cell therapies, an escalating focus on T-cell and NK cell therapies, the broadening of iPSC-based therapeutic applications, an intensifying demand for tailored cell therapy solutions, and strengthened regulatory scrutiny and safety protocols.
Get A Free Sample Report With In-Depth Market Insights:
Allogeneic Cell Therapy Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The allogeneic cell therapy market is anticipated to expand, fueled by the rising occurrence of chronic diseases. These enduring conditions usually necessitate continuous healthcare and have the potential to restrict everyday activities or overall quality of life. The widespread presence of chronic diseases stems from changes in lifestyle, genetic predisposition, and exposure to airborne chemicals, toxins, and pollutants. Allogeneic cell therapy offers considerable promise for addressing numerous chronic illnesses, employing healthy donor cells to mend, substitute, or regulate impaired cells or tissues within the recipient. As an illustration, in January 2023, data from the National Center for Biotechnology Information (NCBI), a US-based medicine library, indicated that the population aged 50 and above experiencing one or more chronic illnesses is projected to rise by 99.5% by 2050, climbing from 71.52 million in 2020 to 142.66 million. Consequently, the expanding incidence of chronic diseases acts as a catalyst for the expansion of the allogeneic cell therapy market.
Allogeneic Cell Therapy Market Segments: Where Is Growth Concentrated?
The allogeneic cell therapy market covered in this report is segmented –
1) By Type: Stem Cell Therapies, Non-Stem Cell Therapies
2) By Therapeutic Area: Hematological Disorders, Dermatological Disorders
3) By End User: Hospitals, Specialty Clinics
Subsegments:
1) By Stem Cell Therapies: Hematopoietic Stem Cell Therapy (Hematopoietic Stem Cells), Mesenchymal Stem Cell Therapy (MSC-Based Therapies), Induced Pluripotent Stem Cells (iPSC-Based Therapies), Neural Stem Cell Therapy
2) By Non-Stem Cell Therapies: T-cell Therapies, Natural Killer (NK) Cell Therapies, Dendritic Cell Therapies
Allogeneic Cell Therapy Market Innovation Trends Shaping Future Development
Leading companies in the allogeneic cell therapy market are concentrating on developing innovative solutions, such as cell processing platforms, to reinforce their market position. Cell processing platforms are defined as systems and technologies employed to prepare and manipulate cells for therapeutic applications, covering processes like isolation, purification, expansion, modification, and quality control, all to ensure cells are appropriate for clinical use. For example, in March 2024, Getinge, a Sweden-based healthcare company, collaborated with CellRev, a UK-based biotechnology company, to introduce Livit ACE, a platform dedicated to continuous cell processing (Adherent Cell Expansion). This advanced platform merges sophisticated automation and bioprocessing technologies, substantially boosting the efficiency and scalability of cell production. Its distinguishing characteristics include cutting-edge cell isolation and purification systems that guarantee high cell purity and viability, powerful expansion capabilities for producing large quantities of therapeutic cells, refined genetic modification tools for precise cell engineering, and strict quality control measures to assure the safety and effectiveness of the cell products.
Allogeneic Cell Therapy Market Key Participants And Competitive Landscape
Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG
View The Full Allogeneic Cell Therapy Market Report:
Allogeneic Cell Therapy Market Geographic Spread And Regional Opportunities
North America was the largest region in the allogeneic cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
